Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.
Alrizomadlin Lands FDA Fast Track Designation for Melanoma
September 23rd 2021Alrizomadlin, a MDM2-p53 inhibitor has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to prior immune-oncologic agents.
FDA Approval Sought for Beti-Cel to Treat B-Thalassemia Requiring Transfusions
September 22nd 2021A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.
FDA Approves Cabozantinib for RAI-Refractory Locally Advanced or Metastatic DTC
September 20th 2021The FDA has approved cabozantinib for the treatment of patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible.
Osimertinib Plus Bevacizumab Does Not Improve PFS in EGFR-Mutated NSCLC
September 18th 2021Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.
Tislelizumab Metastatic ESCC BLA Now Under FDA Consideration for Approval
September 13th 2021The FDA has accepted the biologics license application for tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma in previously treated patients.
Questions Remain Around the Use and Affordability of Telehealth in Oncology
September 7th 2021In an interview with Targeted Oncology, Michael Kolodziej, MD, the senior advisor for ADVI Health as well as an American College of Physicians Fellow, discussed the impact the COVID-19 pandemic has had on oncology practice.
First Patients Dosed in New CA125 Antagonist Study in Ovarian Cancer
September 2nd 2021Two international studies of oregovomab in combination with other anticancer therapies for the treatment of previously treated, recurrent ovarian cancer have dose its first patients, and patients are being recruited to receive the drug in a phase 3 study conducted in the United States.
Tucatinib Detectable in Cerebral Spinal Fluid and Plasma of Patients With HER2+ BC
September 2nd 2021Erica Stringer-Reasor, MD discusses the results of a phase 2 study examining the combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive breast cancer with leptomeningeal metastasis.